What is tirzepatide (GIP/GLP-1) and how is it different from semaglutide?
tirzepatidegipglp1comparison
Tirzepatide is studied as a dual incretin agonist, targeting:
- GIP (glucose-dependent insulinotropic polypeptide) receptor
- GLP-1 receptor
Semaglutide primarily targets the GLP-1 receptor.
In research discussions, the key difference is single-pathway (GLP-1) vs dual-pathway (GIP + GLP-1) signaling.
For research use only. Not medical advice.
Related questions
- What is retatrutide and how is it different from tirzepatide?
- What is the difference between GLP-1, GIP, and glucagon receptors?
- Semaglutide vs tirzepatide vs retatrutide: what’s the difference (research overview)?
- Is tirzepatide “stronger” than semaglutide?
- What are GLP-1 receptor agonists?
- Is semaglutide a GLP-1?
Browse all FAQs about research peptides, sourcing, and Peptide Library.
View all FAQs